Harrison's Manual of Medicine
HEPATOCELLULAR CARCINOMA
To view the entire topic, please log in or purchase a subscription.
Harrison’s Manual of Medicine 20th edition provides 600+ internal medicine topics in a rapid-access format. Download Harrison’s App to iPhone, iPad, and Android smartphone and tablet. Explore these free sample topics:
-- The first section of this topic is shown below --
About 42,030 cases in the United States in 2019, but worldwide this may be the most common tumor; 31,780 deaths in 2019 in the United States. Male:female = 4:1; tumor usually develops in cirrhotic liver in persons in fifth or sixth decade. High incidence (and increasing) in Asia and Africa is related to etiologic relationship between this cancer and hepatitis B and C infections. Effective vaccines for hepatitis B prevention and successful chemotherapy of hepatitis C should reduce the incidence. Aflatoxin exposure contributes to etiology and leaves a molecular signature, a mutation in codon 249 of the gene for p53. Mutations in TERT (telomerase reverse transcriptase) promoter and CTNNB1 (beta-catenin gene) are common.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
About 42,030 cases in the United States in 2019, but worldwide this may be the most common tumor; 31,780 deaths in 2019 in the United States. Male:female = 4:1; tumor usually develops in cirrhotic liver in persons in fifth or sixth decade. High incidence (and increasing) in Asia and Africa is related to etiologic relationship between this cancer and hepatitis B and C infections. Effective vaccines for hepatitis B prevention and successful chemotherapy of hepatitis C should reduce the incidence. Aflatoxin exposure contributes to etiology and leaves a molecular signature, a mutation in codon 249 of the gene for p53. Mutations in TERT (telomerase reverse transcriptase) promoter and CTNNB1 (beta-catenin gene) are common.
There's more to see -- the rest of this topic is available only to subscribers.
